Impact of Subcutaneous Efgartigimod PH20 on Treatment-naïve Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) in the ADHERE Trial: Post Hoc Analyses (P1-9.002)

Neurology 2026

View at publisher
Authors: Jeffrey Allen, Hans Katzberg, Kelly Gwathmey, Ken-ichi Kaida, Satoshi Kuwabara, Yessar Hussain, Arne De Roeck, Benjamin Van Hoorick, Geoffrey Istas, Richard Lewis
DOI: 10.1212/wnl.0000000000215920
Cited by: 1

Abstract

To assess the efficacy of subcutaneous (SC) efgartigimod PH20 among participants in ADHERE with a time since CIDP diagnosis of

Fields of Study & Subjects

Peripheral Neuropathies and Disorders Multiple Sclerosis Research Studies Pituitary Gland Disorders and Treatments

Publication details

Journal / source
Neurology
Publisher
Ovid Technologies (Wolters Kluwer Health)
Volume
106
Issue
11_Supplement_1
Publication date
9 June 2026
Language
EN